New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

Updated May 27th, 2021

New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

The FDA has approved PARP Inhibitor Olaparib for the treatment of advanced prostate cancer patients. Experts say this approval marks new personalized therapy options for specific tumors.

NOW
PLAYING
TODAY anchor AL Roker Shares the Complex Emotions that Came with His Prostate Cancer Diagnosis
NOW
PLAYING
First Melanoma Patient Gets mRNA Cancer Vaccine From Medical Company That Cracked COVID; How Does mRNA Work?
NOW
PLAYING
'Friends's James Michael Tyler is Battling Advanced Prostate Cancer
NOW
PLAYING
The FDA Expedites the Development of New Prostate Cancer Drug
NOW
PLAYING
4 Major Cancer Treatment Advances Happened This Week. Here's What You Missed.
NOW
PLAYING
Major Advance: PARP Inhibitors Extend Life For Women With High Risk Breast Cancer & BRCA Mutations
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.